
Canada · Information technology & services startup
Invixium is a Toronto-based company that designs and manufactures touchless, ruggedized biometric access control solutions.
Funding reportedLast round: Series C
Follow Invixium and see its new rounds in your feed.Start following
Invixium is a Toronto-based company that designs and manufactures touchless, ruggedized biometric access control solutions.
Founded in 2012, Invixium focuses on security, workforce management, visitor screening, and wellness for enterprises, critical infrastructure, and smart buildings. The company operates globally, with offices in India, the USA, UAE, and the UK, serving customers in over 60 countries. Invixium offers multimodal biometric hardware that is dust and water-resistant, suitable for harsh environments. Their key technologies include facial recognition, fingerprint scanning, finger vein recognition, and iris recognition. The IXM TITAN is a notable product that utilizes face recognition as the primary method of authentication. The company also provides a fully integrated software ecosystem, including IXM WEB for analytics and various modules for time tracking and visitor management. Invixium serves a diverse range of industries, including government, banking, healthcare, and smart building automation, enhancing safety, security, productivity, and wellness for its clients.
Funding, as reported
From Invixium's own website: 1 founder, 4 on the team.
What they build
Known for
health careremote monitoringaccess control for enterprisessecuritybiometric device customizationprofessional servicesai-based rtlsbiometric data securitymanufacturingtouchless health screeningmobile credentialssecurity solutionsconstruction & real estateremote biometric managementencryptiondata encryption methods
Built with from their website
Linkedin Sign-inContact Form 7Google Tag ManagerTestLinkWordPress.orgAtlassianGoogle AdsYouTubeMailChimpViewport Meta
Google PlayLocustCookieYesElement UIPerlSageApollo.ioNetSuite
Add your raise, your deck and your story, and put Invixium in front of investors. Or tell us what we have wrong.